CKD Management-Latest and greatest in kidney care

This session will focus on pharmacologic strategies to retard progression of chronic kidney disease (RAS blockade, GLP-1 analogues, SGLT-2 inhibitors, and non-steroidal mineralocorticoid antagonists) as well as treatment of chronic kidney disease complications such as hyperkalemia, chronic kidney disease associated pruritus, and anemia. Since cardiovascular disease is the leading cause of death in patients with chronic kidney disease, this session will also focus on the interplay between chronic kidney disease and cardiovascular disease and pharmacologic and non-pharmacologic interventions to reduce the risk of adverse cardiovascular events in this patient population.

*Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education. The expiration date below is for the product and doest not affect your 90 days access. 

Credits: 1.50 Contact Hours; 1.00 are Pharmacology
This activity is designated for 18 AAPA Category 1 CME credits. Approval is valid from 6/9/2025 to 6/8/2026. PAs should only claim credit commensurate with the extent of their participation.
Expiration Date: June 26, 2026

$35

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

-Describe pharmacologic interventions that retard progression of CKD due to type 2 diabetes mellitus
-Recognize risk factors for hyperkalemia and apply management strategies
-Explain the relationship between cardiovascular disease and chronic kidney disease in type 2 diabetes
-Incorporate new treatment strategies for chronic kidney disease and its complications into primary care practice

CE/CME INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid from 6/9/2025 to 6/8/2026 . 

Accreditation Statement

Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720

This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid from 6/9/2025 to 6/8/2026 . 

DISCLOSURES

Faculty

Contributing faculty, Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP  has disclosed:

Sanofi, Merck, Pfizer, Seqirus, Moderna Speaker bureau and consultant Vaccines All vaccines
GSK/Haleon Consultant Pain Voltaren Gel
AstraZeneca Speaker bureau and consultant Asthma and COPD Airsupra and Breztri

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.